A61K 31/7036
Having at least one amino group directly attached to the carbocyclic ring
Official title: having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
A61K31/7036 (Having at least one amino group directly attached to the carbocyclic ring) appears on 801 US grants and 1,491 published applications in this corpus.
Search patents in A61K- Granted patents
- 801
- Published applications
- 1,491
- Assignees
- 730
- Inventors
- 2,351
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 2 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 2 | 0 |
| 1996 | 1 | 0 |
| 1997 | 2 | 0 |
| 1998 | 5 | 0 |
| 1999 | 4 | 0 |
| 2000 | 3 | 0 |
| 2001 | 8 | 2 |
| 2002 | 9 | 14 |
| 2003 | 7 | 19 |
| 2004 | 5 | 15 |
| 2005 | 9 | 25 |
| 2006 | 6 | 17 |
| 2007 | 3 | 18 |
| 2008 | 5 | 31 |
| 2009 | 7 | 24 |
| 2010 | 15 | 43 |
| 2011 | 14 | 49 |
| 2012 | 15 | 47 |
| 2013 | 33 | 58 |
| 2014 | 47 | 83 |
| 2015 | 42 | 78 |
| 2016 | 62 | 101 |
| 2017 | 55 | 102 |
| 2018 | 60 | 99 |
| 2019 | 52 | 100 |
| 2020 | 69 | 99 |
| 2021 | 52 | 94 |
| 2022 | 47 | 112 |
| 2023 | 54 | 85 |
| 2024 | 42 | 60 |
| 2025 | 40 | 59 |
| 2026 | 24 | 57 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Medication that protects the intestinal microbiota and their preparation methods and applications6 Oct 2026US 12,751,921 B2University of Science and Technology of China
- Combinatory treatment29 Sep 2026US 12,746,216 B2Arivin Therapeutics Oy
- Treatment approach by targeted delivery of bioactive molecules bio modulated ceramics18 Aug 2026US 12,708,603 B2Moroxite AB
- Ionic nanovesicle suspension and biocide prepared therefrom28 Jul 2026US 12,691,176 B2
- Pharmaceutical compositions for prevention and/or treatment of infections and antibacterial-induced dysfunctions30 Jun 2026US 12,668,830 B2European Molecular Biology Laboratory
- Guanidinylated Amphiphilic Tobramycin Derivates and B-Lactam/B-Lactamase Inhibitor Combinations for Treatment of Pseudomonas Aeruginosa Infections8 Oct 2026US 2026/0306524 A1
- Methods for treating corneal injuries1 Oct 2026US 2026/0294849 A1National Taiwan University
- Composition for treating ototoxic hearing loss caused by aminoglycoside antibiotics1 Oct 2026US 2026/0294880 A1Industry-Academic Coorperation Foundation Daegu Haany University
- Aptamer-based sustained release of therapeutic agents1 Oct 2026US 2026/0294954 A1Children's Medical Center Corporation
- Liposome comprising phosphatidylserine, phosphatidic acid and optionally cholesterol, composition and medical use24 Sep 2026US 2026/0284090 A1Biolt S.R.L.S.
Most cited
By later US patents
- Method for manufacturing a porous ceramic scaffold having an organic/inorganic hybrid coating layer containing a bioactive factor777US 8,734,831 B2Snu R&Db Foundation · 2014
- Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth243US 6,861,053 B1Cedars-Sinai Medical Center · 2005
- Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions198US 7,048,906 B2Cedars-Sinai Medical Center · 2006
- Aminoglycoside formulation for aerosolization124US 5,508,269 APathoGenesis Corporation · 1996
- Topical low-viscosity gel composition113US 6,387,383 B1Dow Pharmaceutical Sciences, Inc. · 2002